Elutia Future Growth
Future criteria checks 2/6
Elutia is forecast to grow earnings and revenue by 43.7% and 37.5% per annum respectively while EPS is expected to grow by 51.1% per annum.
Key information
43.7%
Earnings growth rate
51.1%
EPS growth rate
| Biotechs earnings growth | 23.2% |
| Revenue growth rate | 37.5% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 19 Apr 2024 |
Recent future growth updates
Recent updates
News Flash: 2 Analysts Think Elutia Inc. (NASDAQ:ELUT) Earnings Are Under Threat
Mar 10
Elutia Inc.'s (NASDAQ:ELUT) Share Price Is Matching Sentiment Around Its Revenues
Feb 21Little Excitement Around Aziyo Biologics, Inc.'s (NASDAQ:AZYO) Revenues As Shares Take 63% Pounding
Apr 17Aziyo Biologics appoints Williams as Chief Scientific Officer
Aug 26Aziyo Biologics names co-founder C. Randal Mills as permanent CEO
Aug 10Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 84 | 0 | N/A | N/A | 1 |
| 12/31/2025 | 39 | -29 | N/A | N/A | 2 |
| 12/31/2024 | 26 | -34 | N/A | N/A | 2 |
| 12/31/2023 | 25 | -41 | -22 | -22 | N/A |
| 9/30/2023 | 51 | -29 | -18 | -18 | N/A |
| 6/30/2023 | 51 | -31 | -19 | -18 | N/A |
| 3/31/2023 | 51 | -33 | -20 | -19 | N/A |
| 12/31/2022 | 24 | -36 | -22 | -21 | N/A |
| 9/30/2022 | 28 | -39 | -23 | -23 | N/A |
| 6/30/2022 | 34 | -37 | -21 | -20 | N/A |
| 3/31/2022 | 46 | -28 | -18 | -18 | N/A |
| 12/31/2021 | 47 | -25 | -16 | -15 | N/A |
| 9/30/2021 | 49 | -21 | -15 | -14 | N/A |
| 6/30/2021 | 49 | -23 | -13 | -13 | N/A |
| 3/31/2021 | 46 | -26 | -16 | -16 | N/A |
| 12/31/2020 | 43 | -25 | -14 | -14 | N/A |
| 9/30/2020 | 42 | -23 | -12 | -11 | N/A |
| 6/30/2020 | 42 | -16 | -12 | -12 | N/A |
| 3/31/2020 | 43 | -13 | -10 | -9 | N/A |
| 12/31/2019 | 43 | -12 | -8 | -7 | N/A |
| 12/31/2018 | 39 | -12 | -6 | -5 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ELUT is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ELUT is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ELUT is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ELUT's revenue (37.5% per year) is forecast to grow faster than the US market (8.2% per year).
High Growth Revenue: ELUT's revenue (37.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ELUT's Return on Equity is forecast to be high in 3 years time